The present disclosure relates to a method for decoding a combined AM/FM encoded signal, comprising the steps of: combining said encoded optical signal with light from a local oscillator configured with a local oscillator frequency; converting the combined local oscillator and encoded optical signal into one or more electrical signals by means of at least one opto-electrical converter having a predefined frequency bandwidth, thereby providing an amplified and encoded electrical signal having one or more encoded signal current(s), where one type of states have a higher oscillation frequency than other type of states; rectifying the encoded signal current(s), thereby obtaining an encoded power spectrum, wherein said power spectrum has different states, such as "0"-states and "1"-states, with different power levels such that they can be discriminated, said local oscillator frequency is defined by a positive local oscillator frequency-offset from the frequency of one of the states in said encoded optical signal, and said local oscillator frequency-offset is selected to be dependent on said frequency bandwidth.
Solvent consumption in supercritical ethanol, propanol or butanol treatment of either refined pre-extracted lignin or comparatively impure lignin-rich solid residual from hydrothermally pretreated lignocellulosic biomass can be minimized by conducting the reaction at very high loading of lignin to solvent. Comparatively impure, crude lignin- rich solid residual can be directly converted by supercritical alcohol treatment to significantly diesel-soluble lignin oil without requirement for pre-extraction or pre- solubilisation of lignin or for added reaction promoters such as catalysts, hydrogen donor co-solvents, acids, based or H2 gas. O:C ratio of product oil can readily be obtained using crude lignin residual in such a process at levels 0.20 or lower.
C10G 1/04 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal by extraction
C10G 3/00 - Production of liquid hydrocarbon mixtures from oxygen-containing organic materials, e.g. fatty oils, fatty acids
C10L 1/02 - Liquid carbonaceous fuels essentially based on components consisting of carbon, hydrogen, and oxygen only
C10L 1/08 - Liquid carbonaceous fuels essentially based on blends of hydrocarbons for compression ignition
3.
SCANNING AND TRACKING MONITORING APPARATUS AND METHOD
Disclosed is a scanning monitoring apparatus for medical imaging, the scanning monitoring apparatus comprising a controller unit and a display, wherein the controller unit during a scanning session is configured to obtain tracking data (102) of a subject in a medical scanner, obtain scanner data indicative of operating parameters of the medical scanner (104); determine an output of a verification function based on the tracking data and the scanner data (106); and control the scanning monitoring apparatus according to the output of the verification function (108). A notification signal may be provided if the output is indicative of an erroneous scanning.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/113 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb occurring during breathing
4.
SENSOR SYSTEM WITH AN ATTACHMENT ELEMENT FOR A MANNED OR UNMANNED AIRCRAFT
The present disclosure relates to a remote sensing system, comprising: an air towable housing for carrying one or more sensors, the air towable housing and/or a comprising at least a first pulley.
B64C 31/00 - Aircraft intended to be sustained without power plantPowered hang-glider-type aircraftMicrolight-type aircraft
B64D 3/00 - Aircraft adaptations to facilitate towing or being towed
G01V 3/08 - Electric or magnetic prospecting or detectingMeasuring magnetic field characteristics of the earth, e.g. declination or deviation operating with magnetic or electric fields produced or modified by objects or geological structures or by detecting devices
G01V 3/16 - Electric or magnetic prospecting or detectingMeasuring magnetic field characteristics of the earth, e.g. declination or deviation specially adapted for use during transport, e.g. by a person, vehicle or boat specially adapted for use from aircraft
G01V 3/40 - Electric or magnetic prospecting or detectingMeasuring magnetic field characteristics of the earth, e.g. declination or deviation specially adapted for measuring magnetic field characteristics of the earth
5.
GLYCEROL-SILICONE ELASTOMERS AS ACTIVE MATRICES WITH CONTROLLABLE RELEASE PROFILES
Herein is disclosed an elastomeric silicone composition comprising at least a first and a second glycerol phase which are distinct from each other and a method of making the same. The elastomeric compositions are special therein that zero-order active substance release can reversibly be obtained by modifying the glycerol content of the silicone composition.
The present invention relates to microbial factories, in particular yeast factories, for production of ergothioneine. Also provided are methods for producing ergothioneine in a yeast cell, as well as useful nucleic acids, polypeptides, vectors and host cells.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
DANMARKS TEKNISKE UNIVERSITET (Denmark)
Inventor
Sommer, Morten Otto Alexander
Bongers, Mareike
Wang, Harris He
Cusimano, Frank
Abstract
The invention provides a composition for use as a medicament, comprising cells of a recombinant microorganism capable of producing increased amounts of one or more of 5-hydroxytryptophan (5-HTP), 5-hydroxytryptamine (5-HT) and tryptamine (TRM) as compared to the non-recombinant microorganism from which it was derived. The composition finds use in preventing and/or treating TRM-; 5-HTP-, or 5-HT-related disorders of the central nerve system (CNS); enteric nervous system (ENS); gastro intestine (GI) and metabolism in a mammal, and may be orally administered to a mammal in need thereof. Additionally, a composition comprising cells of a recombinant microorganism capable of producing melatonin is provided for use as a medicament, such as for treatment of depression, dementia, cancer and sleep disorder.
The invention regards an apparatus for the separation of dry matter and liquid from a medium, comprising: - a plurality of press rollers and at least one pore roller, - at least one separation chamber for receiving the medium, - at least one filtrate chamber defined in cross section by press rollers and the at least one pore roller, wherein the apparatus is configured: - for establishing a relative negative pressure inside the pore roller interior, such that liquid in the medium is sucked into the pore roller interior, and - for roller rotation such that during separation operation dry matter of the medium initially passes between the pore roller and a press roller when transferring from the separation chamber to the filtrate chamber, and subsequently passes between two press rollers, when exiting from the filtrate chamber.
B01D 33/073 - Filters with filtering elements which move during the filtering operation with rotary cylindrical filtering surfaces, e.g. hollow drums arranged for inward flow filtration
B01D 33/37 - Filters with filtering elements which move during the filtering operation with multiple filtering elements characterised by their mutual disposition in parallel connection
B01D 33/46 - Regenerating the filter material in the filter by scrapers, brushes or the like acting on the cake-side of the filtering element
B01D 33/64 - Handling the filter cake in the filter for purposes other than for regenerating for drying by compression
B01D 33/72 - Filters with filtering elements which move during the filtering operation having feed or discharge devices for feeding
9.
BACTERIAL VEHICLE FOR ENGINEERING OF NON-PHAGOCYTIC IMMUNE CELLS
The invention provides an invasive recombinant bacterial cell for use in prevention and/or treatment of an immune-related disorder; said bacterial cell comprising one or more recombinant nucleic acid molecule(s) encoding one or more therapeutic agent(s) for use in prevention and/or treatment of said immune-related disease in a mammal in need thereof.
The invention relates to microbial cells and microbial cells for use as a medicament, the cells expressing a recombinant nucleic acid encoding a eukaryotic tyrosine hydroxylase. The cells produce L-DOPA and dopamine.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
DANMARKS TEKNISKE UNIVERSITET (Denmark)
Inventor
Andersen, Suzanne Zamany
Li, Katja
Bukas, Vanessa Jane
Saccoccio, Mattia
Krempl, Kevin
Kibsgaard, Jakob
Vesborg, Peter Christian Kjærgaard
Chakraborty, Debashish
Norskov, Jens Kehlet
Chorkendorff, Ib
Statt, Michael
Pedersen, Jakob Bruun
Sazinas, Rokas
Abstract
The invention regards a method for electrochemical ammonia synthesis, comprising the steps of: - providing an electrolysis cell having a cathode, - contacting the cathode with a source of cations, preferably lithium cations, a source of nitrogen, a source of oxygen, and a source of protons, wherein the oxygen source provides a predefined oxygen concentration, and - subjecting the cell to a potential and current load, whereby ammonia is synthesized.
The present disclosure relates to a clinical support system and associated method for automatic real-time detection of clinical deterioration events in a patient. Existing clinical support systems typically rely on alarm generation based on simple threshold values. This often results in too many alarms, including false alarms, which 5consequently results in alarm fatigue in the medical staff or in the ignorance of the alarms. The presently disclosed system and method provides an improved alternative to existing clinical support systems, since it incorporates clinically validated computer-implemented subroutines that provides a higher predictive value to the medical staff. The subroutines utilizes thresholds and time durations, which have been clinically10evaluated such that false alarms are reduced while keeping the most relevant alarms, i.e. alarms that require clinical action. The present disclosure further relates to a computer program configured to execute the disclosed method, thereby providing automatic real-time detection of clinical deterioration events in a patient.
C25B 1/46 - Simultaneous production of alkali metal hydroxides and chlorine, oxyacids or salts of chlorine, e.g. by chlor-alkali electrolysis in diaphragm cells
C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms
C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes
F23J 15/04 - Arrangements of devices for treating smoke or fumes of purifiers, e.g. for removing noxious material using washing fluids
The present disclosure relates, generally, to pteridic acids and derivatives thereof, in particular pteridic acids H, F, and I, their production, and their use to promote plant growth and/or to reduce plant stress, such as abiotic stress.
A01N 43/24 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with two or more hetero atoms
The present disclosure relates to rotatable platform for use in Lab-on-disc (LoD) applications, and LoD microfluidic device having the rotatable platform and which is suitable for analysis of a fluid sample. The present disclosure further relates to real-time monitoring of cells using a centrifugal microfluidic platform. In particular, the present disclosure relates to a mobile LoD device, which can be used in remote destinations and for point of care applications. One embodiment relates to a method for monitoring microorganisms under the constant supply of nutrients, comprising the step of inoculating the cells in a culture chamber in a rotatable microfluidic platform, rotating the platform such that liquid in a reservoir connected to or located on the platform, the liquid comprising nutrients for the cells, is constantly supplied to the cells in the culture chamber by means of shear / centrifugal force resulting from rotating the platform, and continuously monitoring the cells during rotation of the platform by means of imaging, electrochemical and/or electrical measurements.
The present invention relates to a process for producing a isotopically labelled organic compound or a mixture of such compounds in a gas-fed zero-gap electrolyser device.
C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
A system for waste gas treatment is provided. The system for waste gas treatment comprises a photochemical reactor comprising an ultraviolet source. The photochemical reactor is configured to receive a waste gas and to break down, by using the ultraviolet source, the waste gas into one or more primary gaseous by-products. The system for waste gas treatment comprises an absorption reactor. The absorption reactor is connected in series with the photochemical reactor. The absorption reactor is configured to collect and/or convert the one or more primary gaseous by-products into one or more secondary by-products by the use of a liquid containing calcium ions.
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
The present invention relates to engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems and corresponding guide RNAs that target specific nucleotide sequences at certain gene loci in the human genome. Also provided are methods of targeting, editing, and/or modifying of the human genes using the engineered CRISPR systems, and compositions and cells comprising the engineered CRISPR systems.
A method and use of nisin-permeabilized microbial cells as whole-cell catalysts for reducing the amount of a target substrate in a sample to one of more product are provided. Specifically, a method of reducing the amount of lactose in a dairy sample using nisin-permeabilized lactic acid bacterial cell catalysts, which have been permeabilized by incubating with a nisin producing microbial cell and/or culture medium derived therof. Further provided is a nisin producing microbial cell, derived from parent strain Lactococcus lactis subsp. lactis bv. diacetylactis SD96 (NCBI accession No. SRX6686433).
A23C 9/12 - Fermented milk preparationsTreatment using microorganisms or enzymes
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
The invention regards a method for electrochemical ammonia synthesis, comprising the steps of: providing at least one electrolysis cell; contacting the cathode with a source of lithium cations, nitrogen, and protons; and subjecting the cathode to a continuous pulsed cathode potential, including a pulsed cathodic current load, wherein the cathode potential is pulsed between the lithium reduction potential and a less negative cathode potential, whereby ammonia is synthesized.
A permeabilized whole cell catalyst and method for conversion (reducing the amount) of a target substrate to one of more product are provided, wherein the catalyst is obtained by incubating the cells with a permeabilization agent selected from a fatty acid and fatty acid derivative, and wherein the permeabilized cells comprise an intracellular enzyme for catalyzing conversion of the target substrate. The target substrate transits through the channel, holes, or pore made in the cell membrane by the permeabilization agent, and is converted to products by enzymes retained within the cell.
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
The sealing device (1) includes an elongated body (5) adapted to be introduced into a tube-shaped channel (2) and including a sealing fluid placement section (6) arranged between a first and a second annular flow barrier (7, 8). The elongated body further includes a sealing fluid activation section (11) arranged between the second annular flow barrier (8) and a third annular flow barrier (12) and including a sealing fluid activation device (13) adapted to at least initiate or accelerate curing of the sealing fluid (17). In operation, the elongated body may be displaced along the tube-shaped channel until the sealing fluid activation section is placed at a position where sealing fluid has been ejected by the sealing fluid placement section, and the sealing fluid activation device may be activated. Thereby, sealing fluid may be cured at selected locations along the tube- shaped channel after ejection of sealing fluid.
A method and apparatus for surface scanning in medical imaging is provided. The surface scanning apparatus comprises an image source, a first optical fiber bundle comprising first optical fibers having proximal ends and distal ends, and a first optical coupler for coupling an image from the image source into the proximal ends of the first optical fibers, wherein the first optical coupler comprises a plurality of lens elements including a first lens element and a second lens element, each of the plurality of lens elements comprising a primary surface facing a distal end of the first optical coupler, and a secondary surface facing a proximal end of the first optical coupler.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G02B 6/32 - Optical coupling means having lens focusing means
28.
A REINFORCEMENT SYSTEM AND A METHOD OF REINFORCING A STRUCTURE WITH A TENDON
A reinforcement system for anchoring tendons for structural reinforcing a structure such as a concrete structure, said reinforcement system comprises at least one anchor and at least one tendon, said anchor is adapted to fix said tendon in and/or outside said structure, wherein said reinforcement system comprises a ductility element, which is positioned in structural connection between said tendon and said anchor, said ductility element comprising weakened deformation zones being deformable so that the length of the ductility is increased or decreased in an axial direction along the length of said tendon.
The present invention relates to an elastomeric composition comprising a silicone rubber, glycerol, at least one crosslinking agent, and optionally one or more excipients, wherein said glycerol is present as discrete droplets in the silicone rubber, obtainable through the application of high shear forces.
C08J 3/20 - Compounding polymers with additives, e.g. colouring
C08J 9/04 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof using blowing gases generated by a previously added blowing agent
Disclosed is a slurry drying plant (1) comprising a slurry inlet (2) for feeding slurry to the slurry drying plant (1) and two or more meshing screw conveyors (3, 4) arranged to at least partly divide the slurry while conveying the slurry in a transport direction from the slurry inlet (2) to a slurry outlet (5). The slurry drying plant (1) further includes slurry heating means (6) comprising means for passing superheated steam substantially at atmospheric pressure past the slurry and the two or more meshing screw conveyors (3, 4), while they are conveying the slurry. Furthermore, a method for drying slurry and use of a slurry drying plant (1) is disclosed.
F26B 3/06 - Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air the gas or vapour flowing through the materials or objects to be dried
F26B 17/20 - Machines or apparatus for drying materials in loose, plastic, or fluidised form, e.g. granules, staple fibres, with progressive movement with movement performed by rotating helical blades or other rotary conveyors moving materials in stationary chambers the axis of rotation being horizontal or slightly inclined
F26B 21/00 - Arrangements for supplying or controlling air or gases for drying solid materials or objects
F26B 23/02 - Heating arrangements using combustion heating
In certain embodiments a light therapy system (e.g., phototherapy device), such as for treatment of Alzheimer's disease, depression, dementia, short-term memory, or for improved learning, improved athletic performance or improved cognitive performance, is provided where the light system comprises a blue light source that operates at a frequency in the range from 20 to 50 Hz (preferably around 40 Hz), whereby the system enables retinal ganglion cells of a human to be exposed in order to stimulate brain waves (gamma oscillations in the human's brain).
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61M 21/00 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise stabilized MHC class I molecules comprising a heavy chain comprising an alpha-1 domain and an alpha-2 domain connected by a disulfide bridge, wherein said MHC class I molecules are free of antigenic peptide. The scaffolds can be loaded with antigenic peptide on demand, providing an agile platform for effective expansion and functional stimulation of specific T cells in a peptide- MHC-directed fashion.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
The present disclosure relates to rotatable platform for use in Lab-on-disc (LoD) applications, and LoD microfluidic device having the rotatable platform and which is suitable for analysis of a fluid sample. The present disclosure further relates to realtime monitoring of cells using a centrifugal microfluidic platform. In particular, the present disclosure relates to a mobile LoD device, which can be used in remote destinations and for point of care applications. One embodiment relates to a method for monitoring microorganisms under the constant supply of nutrients, comprising the step of inoculating the cells in a culture chamber in a rotatable microfluidic platform, rotating the platform such that liquid in a reservoir connected to or located on the platform, the liquid comprising nutrients for the cells, is constantly supplied to the cells in the culture chamber by means of shear / centrifugal force resulting from rotating the platform, and continuously monitoring the cells during rotation of the platform by means of imaging, electrochemical and/or electrical measurements.
Disclosed is a slurry drying plant (1) comprising a slurry extruder (3) including a slurry inlet (2) and conveying means (4) arranged to convey the slurry through the slurry extruder (3) and force the slurry out of a plurality of exit openings (5) of the slurry extruder (3) to form a plurality of slurry strings (7), wherein the slurry strings (7) are forced out into a drying chamber (8) in which the plurality of slurry strings (7) is dried. The slurry drying plant (1) further comprises slurry heating means (6) comprising flow means for passing superheated steam past the slurry strings (7) in the drying chamber (8), and inlet pressure detection means (9) for detecting a slurry inlet pressure at the slurry inlet (2). The slurry drying plant (1) also comprises control means (17) arranged to control the conveying speed of the conveying means (4) in response to the slurry inlet pressure. Furthermore, a method for drying slurry and use of a slurry drying plant (1) is disclosed.
F26B 1/00 - Preliminary treatment of solid materials or objects to facilitate drying
F26B 3/14 - Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air the materials or objects to be dried being moved by gravity
F26B 17/12 - Machines or apparatus for drying materials in loose, plastic, or fluidised form, e.g. granules, staple fibres, with progressive movement with movement performed solely by gravity
F26B 17/18 - Machines or apparatus for drying materials in loose, plastic, or fluidised form, e.g. granules, staple fibres, with progressive movement with movement performed by rotating helical blades or other rotary conveyors moving materials in stationary chambers
F26B 21/00 - Arrangements for supplying or controlling air or gases for drying solid materials or objects
F26B 23/02 - Heating arrangements using combustion heating
35.
ENGINEERED CELLS FOR PRODUCTION OF INDOLE-DERIVATIVES
Herein are provided microbial factories, in particular yeast factories, for production of strictosidine aglycone and optionally other plant-derived compounds. Also provided are methods for producing strictosidine aglycone in a microorganism, as well as useful nucleic acids, vectors and host cells.
C12N 9/42 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4-glucosidic bonds, e.g. cellulase
C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
C12P 19/44 - Preparation of O-glycosides, e.g. glucosides
37.
FUSION TOXIN PROTEINS FOR TREATMENT OF DISEASES RELATED TO CMV INFECTIONS
The present invention relates to immunotoxins useful in treating diseases related to CMV infection. The invention also relates to use of the immunotoxin and pharmaceutical compositions comprising the immunotoxin as a medicament, and a kit for treatment or prevention of CMV infection comprising the immunotoxin.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 31/22 - Antivirals for DNA viruses for herpes viruses
C07K 14/21 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pseudomonadaceae (F)
The present invention relates to immune stimulating micelle compositions, and their use in treatment of diseases and disorders, such as cancer. In particular, the present invention relates to micelle compositions comprising a TLR7 agonist, such as 1V270.
The present invention relates to an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system comprising engineered dual guide nucleic acids (e.g., RNAs) capable of activating a CRISPR- Associated (Cas) nuclease, such as a type V-A Cas nuclease. Also provided are methods of targeting, editing, and/or modifying a nucleic acid using the engineered CRISPR system, and compositions and cells comprising the engineered CRISPR system.
Described is a method for absorption of gaseous CO2 from a gas stream and desorption of the absorbed CO2, which method comprises contacting said gas stream with a composition at ambient temperature and pressure. The composition comprises: an ionic compound [A+ ][B-] supported on a porous material, wherein [A+] is an ammonium ion +NR1R2R3R4, wherein R1, R2, R3 and R4 are linear C6 alkyl chains, and [B-] is an anion selected from the group consisting of L-lsoleucinate, Glycinate, L-Tyrosinate, and L-Prolinate. The CO2 absorbed on the composition is desorbed by temperature swing absorption (TSA), by increasing the temperature of the composition, by decreasing the total pressure surrounding it and/or by flushing it with a gas stream with no or lower CO2 content than the gas stream originally applied for the absorption.
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
The present disclosure relates to a method and apparatus for X-ray diffraction analysis of amorphous and/or semi-crystalline materials, the method being able to provide the internal strain map of at least the exposed region of the material, even in the amorphous regions of the material. This is achieved in part by providing several unique and novel analysis methods that are able to extract material properties of semi-crystalline and amorphous materials based on the amorphous diffraction signal. The ability to analyse the amorphous diffraction signal is further facilitated by the use of one or more state-of-the-art energy dispersive detectors, which the inventors have found especially suitable for this purpose. This further allows the use of a polychromatic X-ray source as opposed to the monochromatic X-ray sources typically encountered in X-ray diffraction experiments.
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (Germany)
ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (Germany)
UNIVERSITY OF COPENHAGEN (Denmark)
Inventor
Kjaer, Andreas
Herth, Matthias Manfred
Jensen, Andreas Ingemann
Eder, Matthias
Eder, Ann-Christin
Abstract
The present invention provides novel PSMA targeting urea-based ligands that binds to prostate?specific membrane antigen (PSMA) which is expressed 8-to-12-fold higher in prostate cancer cells when compared to healthy tissue. The PSMA targeting urea-based ligands comprises a chelating agent that may comprise a metal and a halogen radioisotope of fluorine, iodine, bromine or astatine. The invention further relates to a method for providing the PSMA targeting urea-based ligands of the invention, to precursors of the PSMA targeting urea-based ligands and to the PSMA targeting urea-based ligands use in radiotherapy, imaging and theranostic.
The present invention relates to thermophilic cells and methods for the microbial production of volatile compounds, including acetone, butanone and isopropanol. Also provided are nucleic acid constructs, vectors and host cells useful in such methods.
The present disclosure relates to a method for producing a multi-material three- dimensional object comprising: computing a number of projections describing the multi- material three-dimensional object to be formed from different orientation angles of said object, including: a number of first projections describing a first part of said object to be formed in a first material; a number of second projections describing a second part of said object to be formed in a second material; providing a build volume comprising: a first photosensitive component capable of polymerizing into the first material upon irradiation by light having a first wavelength; a second photosensitive component capable of polymerizing into the second material upon irradiation by light having a second wavelength, the second material having different mechanical properties than the first material; and irradiating the build volume with a number of patterns of light, as defined by the projections, at the respective corresponding orientations and wavelengths such that the light having the first wavelength deposits energy according to a first energy distribution and wherein the light having the second wavelength deposits energy according to a second energy distribution; thereby physically reproducing said multi-material three-dimensional object.
Provided are methods for increasing the growth of Moorella species bacteria, genetically modified bacteria derived from such methods, and use of such bacteria for metabolizing a carbon-containing substrate, optionally in the production of a biochemical.
The application of geocatalysts in controlling CO2 capture processes in situ as well as in a reaction vessel, chamber or tower is described. More specifically, a process for controlling the reaction of a CO2-containing gas stream with one or more starting materials selected from waste building material, mineral, rock, sand, amorphous material or combinations thereof is disclosed; wherein said starting material comprises Si and/or Al, and one or more divalent cation(s), water, and one or more organic compound(s) to control the reaction; thereby providing a product comprising: at least one carbonate mineral and preferably colloidal silica.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
C25B 11/075 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound
C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
C25B 11/097 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds comprising two or more noble metals or noble metal alloys
C25B 13/02 - DiaphragmsSpacing elements characterised by shape or form
C25B 15/04 - Regulation of the inter-electrode distance
52.
A METHOD OF USING OPTICAL COHERENCE TOMOGRAPHY FOR TRAINING A MACHINE LEARNING MODEL, A METHOD OF DETERMINING AN UNKNOWN CONDITION USING THE TRAINED MODEL, A METHOD OF DETERMINING SEGMENTATION IN A SAMPLE, AND AN OPTICAL COHERENCE TOMOGRAPHY SYSTEM
The invention provides a microbial production cell for synthesis of a product, further comprising a burden-addiction genetic circuit whose expression confers a selective growth and/or survival advantage on those cells that synthesize the product; while limiting proliferation of low- or non-productive escaper cells.
The present invention relates to a method of providing a barrier in a fracture-containing system, comprising: i) Providing a treatment fluid comprising: a) a base fluid; b) an elastomeric material, wherein said elastomeric material comprises at least one polymer capable of crosslinking into an elastomer, and c) at least one crosslinking agent; ii) Placing the treatment fluid in a fracture-containing system; iii) Allowing the elastomeric material to crosslink with itself to form a barrier in said fracture-containing system; wherein the elastomeric material and/or the crosslinking agent are of neutral buoyancy with regard to the base fluid. The invention is contemplated to having utility not only in the oil-drilling industry but also in the plugging of fractures in sewer drains, pipelines etc.
C09K 8/512 - Compositions based on water or polar solvents containing organic compounds macromolecular compounds containing cross-linking agents
C09K 8/516 - Compositions for plastering borehole walls, i.e. compositions for temporary consolidation of borehole walls characterised by their form or by the form of their components, e.g. encapsulated material
C09K 8/575 - Compositions based on water or polar solvents containing organic compounds
patents
